RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS (RESTYLE- HCM STUDY)

Trial Profile

RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS (RESTYLE- HCM STUDY)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2015

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Therapeutic Use
  • Acronyms RESTYLE-HCM
  • Sponsors Menarini
  • Most Recent Events

    • 22 Sep 2012 Planned End Date changed from 3 Jan 2013 to 19 Jan 2013 as reported by European Clinical Trials Database record.
    • 14 Jul 2012 Additional location [Germany] identified as reported by as reported by European Clinical Trials Database.
    • 22 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top